The fusion of quantitative molecular proteomics and<scp>immune‐oncology</scp>: a step towards precision medicine in cancer therapeutics-Reference-Cited by-同舟云学术

The fusion of quantitative molecular proteomics andimmune‐oncology: a step towards precision medicine in cancer therapeutics

Published:2022-09-05 Issue:21 Volume:596 Page:2721-2735
ISSN:0014-5793
Container-title:FEBS Letters
language:en
Short-container-title:FEBS Letters

Author:

Miles James¹²³⁴,Ward Stephen G.⁵,Larijani Banafshé¹²^ORCID

Affiliation:

1. Centre for Therapeutic Innovation, Cell Biophysics Laboratory, Department of Life Sciences, & Department of Physics University of Bath Bath UK

2. Cell Biophysics Laboratory, Research Centre for Experimental Marine Biology and Biotechnology (PiE) & Instituto Biofisika, (UPV/EHU, CSIC) University of the Basque Country Leioa Spain

3. Early Phase Trials and Sarcoma Institut Bergonié, Cours de l'Argonne Bordeaux France

4. FASTBASE Solutions S.L. Astondo Bidea Scientific and Technology Park of Bizkaia Derio Spain

5. Centre for Therapeutic Innovation, Leukocyte Biology Laboratory, Department of Life Sciences University of Bath Bath UK

Funder

Ministerio de Economía y Competitividad

Eusko Jaurlaritza

Publisher

Wiley

Subject

Cell Biology,Genetics,Molecular Biology,Biochemistry,Structural Biology,Biophysics

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/1873-3468.14480

Reference63 articles.

1. Cancer statistics for the year 2020: An overview

2. The Hallmarks of Cancer

3. Treg-mediated acquired resistance to immune checkpoint inhibitors

4. Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review

5. CTLA-4 and PD-1 Pathways

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial functional mapping of hypoxia inducible factor heterodimerisation and immune checkpoint regulators in clear cell renal cell carcinoma;BJC Reports;2024-02-09

2. Spatial Functional Mapping of Hypoxia Inducible Factor Heterodimerisation and Immune checkpoint regulators in clear cell Renal Cell Carcinoma;2023-09-20

3. The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism;Scientific Reports;2023-07-05

4. The role of TOP2A in immunotherapy and Vasculogenic mimicry in non-small cell lung cancer and its potential mechanism;2022-12-05